Skip to Content
Merck
  • Nicotine improves obesity and hepatic steatosis and ER stress in diet-induced obese male rats.

Nicotine improves obesity and hepatic steatosis and ER stress in diet-induced obese male rats.

Endocrinology (2014-02-13)
Patricia Seoane-Collazo, Pablo B Martínez de Morentin, Johan Fernø, Carlos Diéguez, Rubén Nogueiras, Miguel López
ABSTRACT

Nicotine, the main addictive component of tobacco, promotes body weight reduction in humans and rodents. Recent evidence has suggested that nicotine acts in the central nervous system to modulate energy balance. Specifically, nicotine modulates hypothalamic AMP-activated protein kinase to decrease feeding and to increase brown adipose tissue thermogenesis through the sympathetic nervous system, leading to weight loss. Of note, most of this evidence has been obtained in animal models fed with normal diet or low-fat diet (LFD). However, its effectiveness in obese models remains elusive. Because obesity causes resistance towards many factors involved in energy homeostasis, the aim of this study has been to compare the effect of nicotine in a diet-induced obese (DIO) model, namely rats fed a high-fat diet, with rats fed a LFD. Our data show that chronic peripheral nicotine treatment reduced body weight by decreasing food intake and increasing brown adipose tissue thermogenesis in both LFD and DIO rats. This overall negative energy balance was associated to decreased activation of hypothalamic AMP-activated protein kinase in both models. Furthermore, nicotine improved serum lipid profile, decreased insulin serum levels, as well as reduced steatosis, inflammation, and endoplasmic reticulum stress in the liver of DIO rats but not in LFD rats. Overall, this evidence suggests that nicotine diminishes body weight and improves metabolic disorders linked to DIO and might offer a clear-cut strategy to develop new therapeutic approaches against obesity and its metabolic complications.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Bovine TNFα / Tumor Necrosis Factor alpha ELISA Kit, for serum, plasma and cell culture supernatants
L-Threonine, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Threonine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Threonine, BioXtra, ≥99.5% (NT)
Supelco
(−)-Nicotine, PESTANAL®, analytical standard
Supelco
(−)-Nicotine solution, 1.0 mg/mL, analytical standard, for drug analysis
Sigma-Aldrich
L-Threonine, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
L-Threonine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 99.0-101.0%
SAFC
L-Threonine
Sigma-Aldrich
(−)-Nicotine, ≥99% (GC), liquid
Sigma-Aldrich
Mouse Tumor Necrosis Factor α ELISA Kit, for serum, plasma and cell culture supernatant
Supelco
L-Threonine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(±)-Nicotine, ≥99% (TLC), liquid
Sigma-Aldrich
Rat Tumor Necrosis Factor α ELISA Kit, for cell and tissue lysates
Supelco
S(−)-Nicotine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Rat Tumor Necrosis Factor α ELISA Kit, for serum, plasma and cell culture supernatant